thyroid cancer and glp-1 Glucagon-like peptide 1 receptor agonist use risk of cancer: Scandinavian cohort study No Link Seen Between GLP-1
Description
Gorelik et al
(October, 2017) Kelly, T., Yang, W., Chen, C
Should a patient who has been off their weekly GLP1 receptor agonist (e.g., semaglutide or dulaglutide) for a few weeks restart at the same dose if it was previously well tolerated and there are no new contraindications?
We monitor your progress and adjust as needed
They are strengthening long-term commercial demand
